Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Vitiligo and Cancer: Where is the Evidence?
Description
The discussion centers around the relationship between vitiligo and cancer, specifically whether individuals with vitiligo are at a higher risk for skin cancer. The speaker introduces the topic, highlighting existing literature that suggests vitiligo may actually provide some protection against skin cancers such as melanoma and non-melanoma types. Various studies conducted over the years have shown that patients with vitiligo typically exhibit a lower incidence of these skin cancers, and genetic studies indicate that certain genetic markers are linked to this inverse relationship. Furthermore, extensive cohort studies revealed no significant correlation between phototherapy, commonly used in treating vitiligo, and an increased risk of skin cancer, even among patients undergoing extensive treatment. The findings suggest that while vitiligo patients lack melanin, which usually protects against UV damage, other protective mechanisms may exist. The overall message emphasizes the absence of increased skin cancer risk in vitiligo patients and points toward the potential benefits associated with the condition.
View moreConclusions
- Patients with vitiligo have a significantly lower risk of developing skin cancer, including melanoma and non-melanoma skin cancers.
- Genetic studies indicate an inverse relationship between vitiligo and skin cancer risk.
- In cohort studies, patients with vitiligo showed reduced incidence of melanoma and non-melanoma skin cancer, even after adjusting for confounding factors.
- Phototherapy does not seem to increase the risk of skin cancer in patients with vitiligo.
- The long-term use of topical immunomodulators and phototherapy does not raise the risk of skin cancer in vitiligo patients.
- Overall, vitiligo may confer protective effects against certain types of skin cancers.
- Akl, J., Lee, S., Ju, H. J., Parisi, R., Kim, J. Y., Jeon, J. J., Heo, Y. W., Eleftheriadou, V., Hamzavi, I., Griffiths, C. E. M., Ashcroft, D. M., Mysore, V., Gupta, S., Parsad, D., Lim, H., Bae, J. M., Ezzedine, K., on behalf of the Global Vitiligo Atlas. (2022). Estimating the burden of vitiligo: a systematic review and modelling study. J Eur Acad Dermatol Venereol, 36(3), 646-652.
- Jin, Y., Birlea, S. A., Fain, P. R., Gowan, K., Riccardi, S. L., Holland, P. J., Mailloux, C. M., Sufit, A. J. D., Hutton, S. M., Amadi-Myers, A., Bennett, D. C., Wallace, M. R., et al. (2013). Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo. PLoS Genet, 9(8), e1003435. doi:10.1371/journal.pgen.1003435.
- Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., Tomasic, G., Soria, J. C., Champiat, S., Texier, M., Lanoy, E., Robert, C. (2015). Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. J Clin Oncol, 33(24), 2673-2680. doi:10.1200/JCO.2015.62.5144.
- Teulings, H. E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., Luiten, R. M. (2013). Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. J Clin Oncol, 33(24), 2673-2680. doi:10.1200/JCO.2015.62.5144.
- Sobrinoc, L., Russo, N., Abeni, D. (2014). Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol, 71(6), 1110-1116. doi:10.1016/j.jaad.2014.06.027.
- Delcoigne, B., Lysell, J., Askling, J. (2025). Incidence, stage and outcome of melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks? Br J Dermatol, DOI: 10.1093/bjd/ljaf074.